Effects of dulaglutide on thyroid C cells and serum calcitonin in male monkeys

Endocrinology (United States)

Volumn 156, Issue 7, 2015, Pages 2409-2416

  Vahle, John L ^a,b   Byrd, Richard A ^a,b   Blackbourne, Jamie L ^a,b   Martin, Jennifer A ^a,b   Sorden, Steven D ^c   Ryan, Thomas ^c   Pienkowski, Thomas ^c   Wijsman, John A ^a,b   Smith, Holly W ^a,b   Rosol, Thomas J ^d  

^a AmeriPath Indiana   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c 206 Carnegie Center   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; DULAGLUTIDE; KI 67 ANTIGEN; ANTIDIABETIC AGENT; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCONATE CALCIUM; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN WEIGHT; CALCITONIN BLOOD LEVEL; CELL COUNTING; CELL PROLIFERATION; CELL STRUCTURE; CELL VOLUME; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SENSITIVITY; EXPERIMENTAL MONKEY; FOOD INTAKE; MACACA FASCICULARIS; MALE; NONHUMAN; PRIORITY JOURNAL; THYROID PARAFOLLICULAR CELL; THYROID WEIGHT; WEIGHT REDUCTION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; DRUG EFFECTS; ORGAN SIZE; PATHOLOGY; SECRETION (PROCESS); THYROID GLAND;

ANIMALS; CALCITONIN; CALCIUM GLUCONATE; CELL PROLIFERATION; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCAGON-LIKE PEPTIDES; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; MACACA FASCICULARIS; MALE; ORGAN SIZE; RECEPTORS, GLUCAGON; RECOMBINANT FUSION PROTEINS; THYROID GLAND;

EID: 84937598580     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1717     Document Type: Article

References (33)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(suppl 1):S64-S71.
2. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. Centers for Disease Control and Prevention, ed. Atlanta, GA: US Department of Health and Human Services; 2011.
3. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840-846.
4. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378(9785):31-40.
5. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care. 1996;19(6):580-586.
6. Drucker DJ. The biology of incretin hormones. Cell Metabolism. 2006;3(3):153-165.
7. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
8. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987;2(8571):1300-1304.
9. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87(3):1239-1246.
10. Orskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology. 1988;123(4):2009-2013.
11. Egan JM, Bulotta A, Hui H, Perfetti R. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet β cells. Diabet Metab Res Rev. 2003;19(2):115-123.
12. Perfetti R, Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res. 2004;36(11-12):804-810.
13. Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473-1486.
14. Bulchandani D, Nachnani JS, Herndon B, et al. Effect of exendin (exenatide)-GLP 1 receptor agonist on the thyroid and parathyroid gland in a rat model. Eur J Pharmacol. 2012;691(1-3):292-296.
15. [EMA] European Medicnes Agency. European public assessment report: LYXUMIA. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Public-assessment-report/human/002445/WC500140449.pdf. Accessed June 5, 2013.
16. European Medicines Agency (EMA). Summary of product characteristics: LYXUMIA (lixisenatide). 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002445/WC500140401.pdf Accessed August 14, 2013.
17. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide - the FDA's review of a new antidiabetic therapy. N Engl J Med. 2010;362(9):774-777.
18. Mouton PR. Principles and Practices of Unbiased Stereology. An Introduction for Bioscientists. Baltimore, MD: John Hopkins University Press; 2002:88-112.
19. Crissman JW, Goodman DG, Hildebrandt PK, et al. Best practices guideline: toxicologic histopathology. Toxicol Pathol. 2004;32(1):126-131.
20. Winer BJ, Brown DR, Michels KM. Single-Factor Experiments Having Repeated Measures on the Same Elements [Ch. 4]. In: Statistical Principles in Experimental Design. 3rd ed. New York, NY: McGraw-Hill; 1991:220-281.
21. Winer BJ, Brown DR, Michels, KM. Analysis of Covariance [Ch. 10]. Statistical Principles in Experimental Design. 3rd ed. New York, NY: McGraw-Hill; 1991:739-836.
22. Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc. 1955;50:1096-1121.
23. Byrd R, Sorden S, Ryan T, et al. Chronic toxicity and carcinogenicity studies of the long-acting GLP-1 receptor agonist dulaglutide in rodents. Endocrinology. 2015;156(7):2417-2428.
24. Dunnett CW. New tables for multiple comparisons with a control. Biometrics. 1964;20:482-491.
25. Draper NR, Smith H. Applied Regression Analysis. New York, NY: John Wiley & Sons; 1966: 1-127.
26. SAS Institute Inc. Statistical analysis system. 2002-2008, version 9.2. Cary, NC: SAS Institute Inc.
27. Byrd R, Sorden S, Ryan T, et al. Chloride stimulated plasma calcitonin and thyroid C-cell mass, hyperplasia, and neoplasia in rats. Paper presented at the 34th Annual Meeting of the American College of Toxicology, November 3-6, 2013, San Antonio, TX.
28. Peña A, Loghin C, Xuewei C, et al. Pharmacokinetics of once weekly dulaglutide in patients with type 2 diabetes mellitus. American Diabetes Association-74th Annual Scientific Sessions. Diabetes. 2014;63(suppl 1):A251.
29. McConnell EE, Solleveld HA, Swenberg JA, Boorman GA. Guidelines for combining neoplasms for evaluation of rodent carcinogenesis studies. J Natl Cancer Inst. 1986;76(2):283-289.
30. Guerci B, Weinstock R, Umpierrez G, et al. Safety and efficacy of dulaglutide vs sitagliptin after 104 weeks in type 2 diabetes (AWARD-5). Diabetologia. 2013;56(suppl 1):S367.
31. Hegedüs L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab. 2011;96(3):853-860.
32. Negri E, Ron E, Franceschi S, et al. Risk factors for medullary thyroid carcinoma: a pooled analysis. Cancer Causes Control. 2002;13(4):365-372.
33. Swarup K, Das S, Das VK. Thyroid calcitonin cells and parathyroid gland of the Indian rhesus monkey Macaca mulatta in response to experimental hypercalcaemia. Ann Endocrinol (Paris). 1979;40(4):403-412.